Why Jazz Pharmaceuticals Could Be Your Next Long-Term Buy
9/7 04:55
Jazz Pharmaceuticals (NASDAQ: JAZZ) currently trades around $110, down 11% year-to-date, despite a significant positive development of conditional European Commission Marketing Authorization for Ziihera (zanidatamab) for advanced HER2-Positive Biliary Tract Cancer. Ziihera is a f...